Dual FDG and Octreotide PET/CT Imaging in a Patient With Malignant Pheochromocytoma and VHL Gene Mutation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 42029102.
- Also identified by DOI 10.1097/RLU.0000000000006497.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 59-year-old woman with a history of recurrent pheochromocytoma underwent 18 F-FDG and 18 F-octreotide PET/CT to evaluate metastatic disease following progression on targeted therapy. FDG PET/CT showed intense uptake in a mass in the right adrenal bed, bones, lung nodules, and lymph nodes. Octreotide PET/CT confirmed concordant high uptake in the corresponding lesions. Germline testing revealed a VHL p.Asp126Asn mutation. This "dual-tracer" strategy provided complementary information on glucose metabolism and somatostatin receptor expression, facilitating prognostic stratification and therapeutic decision-making in VHL-mutated pheochromocytoma.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Octreotide
- Pheochromocytoma
- Fluorodeoxyglucose F18
- Adrenal Gland Neoplasms
- Mutation
- Von Hippel-Lindau Tumor Suppressor Protein